Arcutis Biotherapeutics, Inc.
ARQT
Clasificación en acciones
#4010
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Precio por acción
$32.29
Última sincronización: 2026-10-19
Capitalización bursátil
$4.06B
Cambio (1 día)
12.02%
Cambio (1 año)
54.62%
País
US
Comercio Arcutis Biotherapeutics, Inc. (ARQT)
Categoría
Healthcare
Ratio P/S de Arcutis Biotherapeutics, Inc. (ARQT)
Ratio P/S al October 2026 TTM: 7.15
Según los informes financieros más recientes y el precio de las acciones de Arcutis Biotherapeutics, Inc., el ratio P/S actual (TTM) es 7.15. Al final de 2023, el ratio P/S era 3.76.
Historial del ratio P/S de Arcutis Biotherapeutics, Inc. desde 2017 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 7.15 | -16.55% |
| 2024 | 8.57 | 128.27% |
| 2023 | 3.76 | -98.30% |
| 2022 | 220.96 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | 40.14% |
US
|
|
| 40.55 | 467.01% |
US
|
|
| 3.96 | -44.61% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 41.87% |
NL
|
